HEIGHT OF GROWTH DELAYED CHILDREN WITH ACTIVE CROHN'S DISEASE IMPROVES DURING TREATMENT WITH INFLIXIMAB
Bibliographic record
Abstract
Delayed linear growth is a common problem in children with moderately to severely active Crohn's disease. The effect of infliximab on growth was examined in children with growth delay at the time of entry into the REACH study (a multicenter, randomized, open-label study that evaluated infliximab therapy in children with moderately to severely active Crohn's disease). Children (n = 112) with a Pediatric Crohn's Disease Activity Index score >30 received infliximab 5 mg/kg induction treatment at weeks 0, 2, and 6. Patients responding to induction treatment assessed by the principal investigators at week 10 (n = 103) were randomized to receive infliximab 5 mg/kg every 8 weeks or every 12 weeks through week 46 and followed through week 54. Height status z scores, which adjust for age and gender, were calculated using the SEER database at baseline, and Weeks 30 and 54 for the subgroup of children with at least a 1 year delay in bone age (as measured by a wrist radiograph) at the time of study entry (n = 38). At week 0, the median height status z score was −1.6 and the mean height status z score was −1.5. The mean height status z scores were significantly improved from baseline at both Week 30 (mean = 0.3, p < 0.001) and Week 54 (mean = 0.5, p < 0.001), in the combined infliximab dose groups. At Week 54, the improvement in height status was greater in patients in the every 8 week maintenance treatment group with 43.5% improving their z score by at least 0.5 standard deviation and 13.0% improving their z score by at least 1 standard deviation in contrast to 20.0% and 6.7% respectively in the q12 week maintenance treatment group. Infliximab significantly improved the height status of children with moderately to severely active Crohn's disease who had a 1 year delay in bone age.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".